In patients with severe refractory psoriasis, treatment with recombinant human interleukin-4 (rhuIL-4) provides significant clinical benefit, and may represent a new therapeutic approach to other Th1-associated autoimmune diseases.
That’s according to a report in the January issue of Nature Medicine posted online December 2nd. “This is the first clinical trial where IL-4 was given for the treatment of an inflammatory autoimmune disease in humans,” team leader Dr. Martin Rcken of Eberhard Karls University Tuebingen, Germany, noted in comments to Reuters Health.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!